Medical Program: Comparing Anti-EGFR in Left vs. Right-Sided Colorectal Cancer Tumors: Survival Trends from the Latest Clinical

Comparing Anti-EGFR in Left vs. Right-Sided Colorectal Cancer Tumors: Survival Trends from the Latest Clinical Trials

Comparing Anti-EGFR in Left vs. Right-Sided Colorectal Cancer Tumors: Survival Trends from the Latest Clinical Trials
RestartResume

Colorectal cancer patients receiving anti-EGFR therapies are seeing improved survival rates, but how do those rates vary based on tumor sidedness?

  • Overview

    Here to give us a breakdown of what the latest clinical trials are saying about anti-EGFR therapies in left versus right-sided colorectal cancer tumors is Dr. Putao Cen, Associate Professor of Medical Oncology at the University of Texas Health Science Center McGovern Medical School.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free